Effects of Calcium and Annatto Tocotrienol Supplementation on Bone Loss Induced by Pantoprazole in Male Rats

References

• YuLY, SunLN, ZhangXH, et al. A review of the novel application and potential adverse effects of proton pump inhibitors. Adv Ther. 2017;34(5):1070–1086. doi:10.1007/s12325-017-0532-928429247
   PubMed Web of Science ®Google Scholar
• FuentesAV, PinedaMD, VenkataKCN. Comprehension of top 200 prescribed drugs in the US as a resource for pharmacy teaching, training and practice. Pharmacy. 2018;6(2):43.
   Web of Science ®Google Scholar
• ShinJM, SachsG. Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep. 2008;10(6):528–534. doi:10.1007/s11894-008-0098-419006606
   PubMedGoogle Scholar
• EusebiLH, RabittiS, ArtesianiML, et al. Proton pump inhibitors: risks of long-term use. J Gastroenterol Hepatol. 2017;32(7):1295–1302.28092694
   PubMed Web of Science ®Google Scholar
• ThongBKS, Ima-NirwanaS, ChinKY. Proton pump inhibitors and fracture risk: a review of current evidence and mechanisms involved. Int J Environ Res Public Health. 2019;16(9):E1571. doi:10.3390/ijerph1609157131060319
   PubMed Web of Science ®Google Scholar
• DaiZ, KohW-P. B-vitamins and bone health-a review of the current evidence. Nutrients. 2015;7(5):3322–3346. doi:10.3390/nu705332225961321
   PubMed Web of Science ®Google Scholar
• LiuJ, LiX, FanL, et al. Proton pump inhibitors therapy and risk of bone diseases: an update meta-analysis. Life Sci. 2019;218:213–223. doi:10.1016/j.lfs.2018.12.05830605646
   PubMed Web of Science ®Google Scholar
• ZhouB, HuangY, LiH, SunW, LiuJ. Proton-pump inhibitors and risk of fractures: an update meta-analysis. Osteoporos Int. 2016;27(1):339–347. doi:10.1007/s00198-015-3365-x26462494
   PubMed Web of Science ®Google Scholar
• NassarY, RichterS. Proton-pump inhibitor use and fracture risk: an updated systematic review and meta-analysis. J Bone Metab. 2018;25(3):141–151. doi:10.11005/jbm.2018.25.3.14130237993
   PubMedGoogle Scholar
• PolyTN, IslamMM, YangHC, WuCC, LiYJ. Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies. Osteoporos Int. 2019;30(1):103–114. doi:10.1007/s00198-018-4788-y30539272
   PubMed Web of Science ®Google Scholar
• FriedmanAW. Important determinants of bone strength: beyond bone mineral density. J Clin Rheumatol. 2006;12(2):70–77. doi:10.1097/01.rhu.0000208612.33819.8c16601540
   PubMed Web of Science ®Google Scholar
• BerrySD, KielDP. Chapter 33 - falls as risk factors for fracture In: MarcusR, FeldmanD, DempsterDW, LuckeyM, CauleyJA, editors. Osteoporosis. Fourth ed. San Diego: Academic Press; 2013:803–815.
   Google Scholar
• Administration UFaD. FDA drug safety communication: possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors. Published 2011 Available from: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fda-drug-safety-communication-possible-increased-risk-fractures-hip-wrist-and-spine-use-proton-pump#AdditionalInformationforPatientsandConsumers. Accessed 622, 2020.
   Google Scholar
• YangY-X. Chronic proton pump inhibitor therapy and calcium metabolism. Curr Gastroenterol Rep. 2012;14(6):473–479. doi:10.1007/s11894-012-0290-423054811
   PubMedGoogle Scholar
• ZhaoJ-G, ZengX-T, WangJ, LiuL. Association between calcium or vitamin D supplementation and fracture incidence in community-dwelling older adults: a systematic review and meta-analysis. JAMA. 2017;318(24):2466–2482. doi:10.1001/jama.2017.1934429279934
   PubMed Web of Science ®Google Scholar
• Bischoff-FerrariHA, Dawson-HughesB, WillettWC. Issues of trial selection and subgroup considerations in the recent meta-analysis of Zhao and colleagues on fracture reduction by calcium and vitamin D supplementation in community-dwelling older adults. Osteoporosis Int. 2018;29(9):2151–2152. doi:10.1007/s00198-018-4587-5
   PubMed Web of Science ®Google Scholar
• WongSK, ChinKY, SuhaimiFH, AhmadF, Ima-NirwanaS. Exploring the potential of tocotrienol from Bixa orellana as a single agent targeting metabolic syndrome and bone loss. Bone. 2018;116:8–21. doi:10.1016/j.bone.2018.07.00329990585
   PubMed Web of Science ®Google Scholar
• MohamadNV, Ima-NirwanaS, ChinKY. Effect of tocotrienol from Bixa orellana (annatto) on bone microstructure, calcium content, and biomechanical strength in a model of male osteoporosis induced by buserelin. Drug Des Devel Ther. 2018;12:555–564. doi:10.2147/DDDT.S158410
   PubMed Web of Science ®Google Scholar
• ChinKY, Ima-NirwanaS. Effects of annatto-derived tocotrienol supplementation on osteoporosis induced by testosterone deficiency in rats. Clin Interv Aging. 2014;9:1247–1259. doi:10.2147/CIA.S6701625120355
   PubMed Web of Science ®Google Scholar
• FregaN, MozzonM, BocciF. Identification and estimation of tocotrienols in the annatto lipid fraction by gas chromatography-mass spectrometry. J Am Oil Chem Soc. 1998;75(12):1723–1727. doi:10.1007/s11746-998-0323-1
   Web of Science ®Google Scholar
• Wan HasanWN, ChinK-Y, Abd GhafarN, SoelaimanIN. Annatto-derived tocotrienol promotes mineralisation of MC3T3-E1 cells by enhancing BMP-2 protein expression via inhibiting RhoA activation and HMG-CoA reductase gene expression. Drug Des Devel Ther. 2020;14:969–976. doi:10.2147/DDDT.S224941
   PubMed Web of Science ®Google Scholar
• Wan HasanWN, Abd GhafarN, ChinKY, Ima-NirwanaS. Annatto-derived tocotrienol stimulates osteogenic activity in preosteoblastic MC3T3-E1 cells: a temporal sequential study. Drug Des Devel Ther. 2018;12:1715–1726.
   PubMed Web of Science ®Google Scholar
• ShenCL, YangS, TomisonMD, RomeroAW, FeltonCK, MoH. Tocotrienol supplementation suppressed bone resorption and oxidative stress in postmenopausal osteopenic women: a 12-week randomised double-blinded placebo-controlled trial. Osteoporos Int. 2018;29(4):881–891. doi:10.1007/s00198-017-4356-x29330573
   PubMed Web of Science ®Google Scholar
• MetzDC, SofferE, ForsmarkCE, et al. Maintenance oral pantoprazole therapy is effective for patients with Zollinger-Ellison syndrome and idiopathic hypersecretion. Am J Gastroenterol. 2003;98(2):301–307. doi:10.1111/j.1572-0241.2003.07262.x12591045
   PubMed Web of Science ®Google Scholar
• AndreolloNA, SantosEF, AraújoMR, LopesLR. Rat’s age versus human’s age: what is the relationship? Arq Bras Cir Dig. 2012;25(1):49–51. doi:10.1590/S0102-6720201200010001122569979
   PubMedGoogle Scholar
• Reagan-ShawS, NihalM, AhmadN. Dose translation from animal to human studies revisited. FASEB J. 2008;22(3):659–661. doi:10.1096/fj.07-9574LSF17942826
   PubMed Web of Science ®Google Scholar
• SaifA, NorazlinaM, Ima NirwanaS. Quantification of bone histomorphometric parameters using the weibel technique in animals. Med Health. 2016;11(2):278–288. doi:10.17576/MH.2016.1102.16
   Google Scholar
• MatuszewskaA, NowakB, RzeszutkoM, et al. Effects of long-term administration of pantoprazole on bone mineral density in young male rats. Pharmacol Rep. 2016;68(5):1060–1064. doi:10.1016/j.pharep.2016.06.01227552060
   PubMed Web of Science ®Google Scholar
• VeggerJB, BruelA, ThomsenJS. Pantoprazole, a proton pump inhibitor, does not prevent botulinum toxin induced disuse osteopenia in mice. J Musculoskelet Neuronal Interact. 2017;17(3):162–175.28860418
   PubMed Web of Science ®Google Scholar
• HuangH, LiuL, ZhaoZ, FuFU, WangW, XuQ. Protective effects of moderate Ca supplementation against Cd-induced bone damage under different population-relevant doses in young female rats. Nutrients. 2019;11(4):849. doi:10.3390/nu11040849
   PubMed Web of Science ®Google Scholar
• MohamadNV, SoelaimanIN, ChinKY. Effects of tocotrienol from Bixa orellana (annatto) on bone histomorphometry in a male osteoporosis model induced by buserelin. Biomed Pharmacother. 2018;103:453–462. doi:10.1016/j.biopha.2018.04.08329674281
   PubMed Web of Science ®Google Scholar
• SuntornsaratoonP, CharoenphandhuN, KrishnamraN. Fortified tuna bone powder supplementation increases bone mineral density of lactating rats and their offspring. J Sci Food Agric. 2018;98(5):2027–2034. doi:10.1002/jsfa.868828940514
   PubMed Web of Science ®Google Scholar
• Abdul-MajeedS, MohamedN, SoelaimanIN. The use of delta-tocotrienol and lovastatin for anti-osteoporotic therapy. Life Sci. 2015;125:42–48. doi:10.1016/j.lfs.2014.12.01225534439
   PubMed Web of Science ®Google Scholar
• AllenMR, BurrDB. Chapter 8 - techniques in histomorphometry In: BurrDB, AllenMR, editors. Basic and Applied Bone Biology. (Second ed. Academic Press; 2019:141–158.
   Google Scholar
• PrauseM, SeeligerC, UngerM, Rosado BalmayorE, van GriensvenM, HaugAT. Pantoprazole decreases cell viability and function of human osteoclasts in vitro. Mediators Inflamm. 2015;2015:413097. doi:10.1155/2015/41309725873758
   PubMed Web of Science ®Google Scholar
• PrauseM, SeeligerC, UngerM, van GriensvenM, HaugAT. Pantoprazole increases cell viability and function of primary human osteoblasts in vitro. Injury. 2014;45(8):1156–1164. doi:10.1016/j.injury.2014.05.00524893920
   PubMed Web of Science ®Google Scholar
• ChinKY, Abdul-MajeedS, MohamedN, Ima-NirwanaS. The effects of tocotrienol and lovastatin Co-supplementation on bone dynamic histomorphometry and bone morphogenetic protein-2 expression in rats with estrogen deficiency. Nutrients. 2017;9(2):E143. doi:10.3390/nu902014328212283
   PubMed Web of Science ®Google Scholar
• ChinKY, Abdul-MajeedS, FoziNF, Ima-NirwanaS. Annatto tocotrienol improves indices of bone static histomorphometry in osteoporosis due to testosterone deficiency in rats. Nutrients. 2014;6(11):4974–4983. doi:10.3390/nu611497425389899
   PubMed Web of Science ®Google Scholar
• HistingT, StengerD, ScheuerC, et al. Pantoprazole, a proton pump inhibitor, delays fracture healing in mice. Calcif Tissue Int. 2012;90(6):507–514. doi:10.1007/s00223-012-9601-x22527206
   PubMed Web of Science ®Google Scholar
• ChinKY, GengatharanD, Mohd NasruFS, et al. The effects of annatto tocotrienol on bone biomechanical strength and bone calcium content in an animal model of osteoporosis due to testosterone deficiency. Nutrients. 2016;8(12):E808.27983628
   PubMed Web of Science ®Google Scholar
• MasubuchiN, LiAP, OkazakiO. An evaluation of the cytochrome P450 induction potential of pantoprazole in primary human hepatocytes. Chem Biol Interact. 1998;114(1):1–13. doi:10.1016/S0009-2797(98)00031-39744552
   PubMed Web of Science ®Google Scholar
• AbeC, UchidaT, OhtaM, IchikawaT, YamashitaK, IkedaS. Cytochrome P450-dependent metabolism of vitamin E isoforms is a critical determinant of their tissue concentrations in rats. Lipids. 2007;42(7):637–645. doi:10.1007/s11745-007-3064-217520307
   PubMed Web of Science ®Google Scholar
• WangZ, LinYS, ZhengXE, et al. An inducible cytochrome P450 3A4-dependent vitamin D catabolic pathway. Mol Pharmacol. 2012;81(4):498–509. doi:10.1124/mol.111.07635622205755
   PubMed Web of Science ®Google Scholar